Eureka Therapeutics will advance its T-cell treatment for relapsed and refractory CD19+ non-Hodgkin lymphoma into the clinic.

Chinese biotech Innovent Biologics is reportedly considering a $200 million IPO later this year that could take place in the U.S.

Neurogastrx grabbed $45 million to bring its gastroparesis drug through proof of concept.

Next year will be a busy time for the European Medicines Agency as it looks to complete its move to Amsterdam.

Will this year’s resurgence be sustained in 2018 in the face of a more uncertain environment?

While 2016 was a year of cancelled and low-end IPOs, 2017 was a year marked by IPO momentum.

If you took charge of a sizable biopharma company in 2017, there was one thing you had to do.

The former CEO of Tennessee biotech Provectus treated the company as his “personal piggy bank,” taking millions from the business, says the SEC.

PsiOxus Therapeutics has a green light for trials of its cancer-killing virus therapy for solid tumors, sparking a $15 million milestone payment.